Search inquiry: <.>II=ЕУ12/2021/43/1<.> |
Total number of found documents : 19
Shown documents from 1 till 19 |
>1.
| A non-coding cancer mutation disrupting an HNF4α binding motif affects an enhancer regulating genes associated to the progression of liver cancer/M. Cavalli [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.2-7
|
>2.
| Ada Leonidivna Vorontsova (1934–2020) // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.96
|
>3.
| An uncommon case of vulvar cancer metastatic to breast/M. Moreno [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.92-95
|
>4.
| Application of gold and silver nanoparticles for selective assay of spermine in mixture with spermidine/Yu. V. Yanish [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.77-81
|
>5.
| Changes in expression of TLR-4, TGF-β, INF-γ, TNF-α in cultured T24/83 cells of invasive bladder cancer treated with cisplatin and/or polyphenolic adjuvant melanin/P. G. Yakovlev [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.7-14
|
>6.
| Comparative study of biochemical and morphological parameters in rats with Walker 256 and Walker 256/DOX carcinosarcoma/L. A. Yushko [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.21-25
|
>7.
| Emergency oncology admissions during COVID-19 pandemic: a major institution experience from Saudi Arabia/O. Elemam [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.31-35
|
>8.
| Erythropoietin as an independent prognostic factor in myelodysplastic syndromes/O. Boyko [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.41-45
|
>9.
| Experience and prospects for the use of off-label drugs in oncology/S. M. Drogovoz [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.82-86
|
>10.
| Experience with the use of HIPEC in advanced serous ovarian cancer after complete and optimal cytoreduction/N. P. Tsip [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.67-72
|
>11.
| Immunodeficiency-associated lymphoproliferative disorders and lymphoid neoplasms in post-COVID-19 pandemic era/D. F. Gluzman [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.87-91
|
>12.
| Macrophage polarization in dynamics of Lewis lung carcinoma growth and metastasis/A. V. Chumak [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.15-20
|
>13.
| New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients/P. Gervas [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.52-55
|
>14.
| Gurianov D. S. Nuclear localization of BCR and cortactin indicates their potential role in regulation of actin branching in nucleus/D. S. Gurianov, S. V. Antonenko, G. D. Telegeev // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.73-76
|
>15.
| Ornithine decarboxylase activity in prostate cancer/О. А. Samoylenko [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.46-51
|
>16.
| Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue/O. E. Lobanova [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.56-60
|
>17.
| ROS production by circulating phagocytes and Guerin carcinoma resistance to cisplatin/I. V. Prokhorova [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.26-30
|
>18.
| Significance of expression of tumor-associated microRNA-21 and -375 for predicting the course of cancer of oral cavity/O. V. Kravets [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.36-40
|
>19.
| Therapeutic results and prognostic factors of stage III NSCLC: a population-based study in Tunisia/K. Hergebue [та ін.] // Экспериментальная онкология, 2021. т.Т. 43,N № 1.-С.61-66
|
|